Publications by authors named "Vincent Balanag"

Claim this Profile
E
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial.
Nicholas I Paton, Christopher Cousins, Intan P Sari, Erlina Burhan, Nan-Kai Ng, Vincent M Balanag

Lancet Infect Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET-CT outcomes from a randomised controlled trial of rosuvastatin as an adjunct to standard tuberculosis treatment.
Gail B Cross, Intan P Sari, Sarah M Burkill, Chee Woei Yap, Han Nguyen, Vincent M Balanag

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Muge Cevik, Lindsay C Thompson, Caryn Upton, Valéria Cavalcanti Rolla, Mookho Malahleha, Vincent Balanag

Lancet Infect Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
Gail B Cross, Intan P Sari, Cissy Kityo, Qingshu Lu, Yogesh Pokharkar, Vincent M Balanag

Lancet Infect Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Nicholas I Paton, Christopher Cousins, Celina Suresh, Erlina Burhan, Ka Lip Chew, Vincent M Balanag

N Engl J Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
Florian von Groote-Bidlingmaier, Ramonde Patientia, Epifanio Sanchez, Vincent Balanag, Eduardo Ticona

Lancet Respir Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment.
Qin Liu, Katharine Abba, Marissa M Alejandria, David Sinclair, Vincent M Balanag

Cochrane Database Syst Rev· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of obstructive lung disease in a rural setting in the Philippines.
Luisito F Idolor, Teresita S DE Guia, Norberto A Francisco, Camilo C Roa, Fernando G Ayuyao, Vincent M Balanag

Respirology· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reminder systems and late patient tracers in the diagnosis and management of tuberculosis.
Qin Liu, Katharine Abba, Marissa M Alejandria, Vincent M Balanag, Regina P Berba

Cochrane Database Syst Rev· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis